Skip to content

Clinical research on improving the quality of life and exercise tolerance of patients with pneumoconiosis with breathing-guided rehabilitation technology: A prospective clinical study

Clinical research on improving the quality of life and exercise tolerance of patients with pneumoconiosis with breathing-guided rehabilitation technology: A prospective clinical study

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2200063723
Enrollment
Unknown
Registered
2022-09-15
Start date
2022-09-15
Completion date
Unknown
Last updated
2023-04-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

pneumoconiosis

Interventions

Group 1 :Western medicine symptomatic treatment + pulmonary Daoyin
Group 2:Western medicine symptomatic treatment + exercise training
Group 3:Western medicine symptomatic treatment

Sponsors

The First Affiliated Hospital of Henan University of Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. According to the medical history and related examinations, a patient with coal worker pneumoconiosis was diagnosed; 2. Age 18-75 years old; 3. Voluntarily sign the informed consent form.

Exclusion criteria

Exclusion criteria: 1. Persons who are not out of dust contact; 2. Patients with active pulmonary tuberculosis, idiopathic pulmonary fibrosis, bronchial asthma, bronchiectasis, pulmonary embolism, chronic respiratory failure or other severe respiratory diseases; 3. Patients with acute exacerbation within 1 month before enrollment; 4. Patients with severe cardiovascular and cerebrovascular diseases (malignant arrhythmia, unstable angina, acute myocardial infarction, cardiac function grade 3 and above, stroke, cerebral hemorrhage, etc.); 5. Combined with severe liver and kidney disease (serious liver disease refers to liver cirrhosis, portal hypertension and variceal bleeding, severe kidney disease includes dialysis, kidney transplantation); 6. Tumor patients who have undergone resection, radiotherapy and chemotherapy within 5 years; 7. Patients with activity difficulties caused by neuromuscular diseases; 8. Combined with severe arthritis; 9. Combined with severe peripheral vascular disease; 10. Pregnant and lactating women; 11. Combined with severe cognitive and mental abnormalities; 12. Clinical investigators who are participating in other interventions within one month before enrollment.

Design outcomes

Primary

MeasureTime frame
exercise capacity;quality of life;

Secondary

MeasureTime frame
severity of dyspnea;pulmonary function;Other health-related quality of life;

Countries

China

Contacts

Public ContactLi Jiansheng

The First Affiliated Hospital of Henan University of Chinese Medicine

li-js8@163.com+86 13703717893

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026